Literature DB >> 25063555

The 2 × 2 cluster randomized controlled factorial trial design is mainly used for efficiency and to explore intervention interactions: a systematic review.

Noreen D Mdege1, Sally Brabyn2, Catherine Hewitt3, Rachel Richardson2, David J Torgerson3.   

Abstract

OBJECTIVES: To describe the health care settings, purposes, and study reporting quality of the 2 × 2 cluster randomized controlled factorial trial design. STUDY DESIGN AND
SETTING: This study is a systematic review. We searched Medline, Embase, Cochrane Library, and Web of Knowledge for articles published up to May 2012. Cluster randomized controlled 2 × 2 factorial trials in health, evaluating at least one complex intervention, were included. Two authors independently reviewed and extracted data from the studies.
RESULTS: Twenty-nine studies covering a wide range of clinical areas and health care settings were included. The cluster design was mostly used to minimize contamination. The factorial design was mostly used to assess the effects of two interventions in the same study and to explore interactions between interventions. However, although most studies explored the presence or absence of intervention interactions, they were often either not sufficiently powered to detect any interactions or did not provide information on whether the study was sufficiently powered to detect any interactions. There was a considerable variability in the reporting of a number of study characteristics and methodological aspects. Study quality was also variable within and across studies.
CONCLUSION: The design has been used in a wide range of health care settings and clinical areas to minimize contamination, assess the effects of two interventions in the same study, and explore intervention interactions. There is need for improvement on and guidelines for the reporting of factorial trials.
Copyright © 2014 Elsevier Inc. All rights reserved.

Keywords:  2 × 2; Cluster randomized; Complex interventions; Factorial; Randomized controlled trial; Systematic review

Mesh:

Year:  2014        PMID: 25063555     DOI: 10.1016/j.jclinepi.2014.06.004

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  6 in total

Review 1.  Review of Recent Methodological Developments in Group-Randomized Trials: Part 1-Design.

Authors:  Elizabeth L Turner; Fan Li; John A Gallis; Melanie Prague; David M Murray
Journal:  Am J Public Health       Date:  2017-04-20       Impact factor: 9.308

2.  Sample size calculation in hierarchical 2 × 2 factorial trials with unequal cluster sizes.

Authors:  Zizhong Tian; Denise Esserman; Guangyu Tong; Ondrej Blaha; James Dziura; Peter Peduzzi; Fan Li
Journal:  Stat Med       Date:  2022-01-02       Impact factor: 2.373

3.  Influential methods reports for group-randomized trials and related designs.

Authors:  David M Murray
Journal:  Clin Trials       Date:  2022-01-06       Impact factor: 2.599

4.  The PrEPARE Pretoria Project: protocol for a cluster-randomized factorial-design trial to prevent HIV with PrEP among adolescent girls and young women in Tshwane, South Africa.

Authors:  Wendee M Wechsberg; Felicia A Browne; Jacqueline Ndirangu; Courtney Peasant Bonner; Alexandra M Minnis; Laura Nyblade; Ilene S Speizer; Brittni N Howard; Bronwyn Myers; Khatija Ahmed
Journal:  BMC Public Health       Date:  2020-09-15       Impact factor: 3.295

5.  Acupuncture and clomiphene for Chinese women with polycystic ovary syndrome (PCOSAct): statistical analysis approach with the revision and explanation.

Authors:  Hong-Li Ma; Liang-Zhen Xie; Jing-Shu Gao; Jing Cong; Ying-Ying Deng; Ernest H Y Ng; Jian-Ping Liu; Xiao-Ke Wu
Journal:  Trials       Date:  2018-11-01       Impact factor: 2.279

6.  Impact of nonclinical factors on intensive care unit admission decisions: a vignette-based randomized trial (V-TRIAGE).

Authors:  João Gabriel Rosa Ramos; Otavio Tavares Ranzani; Roger Daglius Dias; Daniel Neves Forte
Journal:  Rev Bras Ter Intensiva       Date:  2021 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.